11:50 AM EST - QLT Inc. : announced that its commercial product, Visudyne® (verteporfin for injection), was granted orphan drug designation for the potential treatment of chronic or recurrent central serous chorioretinopathy (CSC) from the U.S. Food and Drug Administration (FDA). QLT Inc.
shares T.QLT are trading unchanged at $7.20.
